Title: HOUSE BILL 813
Official Title: HOUSE BILL 813
Number of Sections: 1
Source: versions - Enrolled - Maryland Insurance Administration and Maryland Department of Health - Workgroup to Study Pharmacy Benefits Managers
Media Type: application/pdf
Strikethrough Detection: 6 sections found

================================================================================

Section 1:
J5 EMERGENCY BILL (5lr2785)
ENROLLED BILL
— Health and Government Operations/Finance —
Introduced by Delegates S. Johnson and A. Johnson, A. Johnson, Alston, Bagnall,
Bhandari, Cullison, Guzzone, Hill, Hutchinson, Kaiser, Kerr, Kipke, Lopez,
Martinez, M. Morgan, Pena–Melnyk, Reilly, Rosenberg, Ross, Szeliga,
Taveras, White Holland, Woods, and Woorman
Read and Examined by Proofreaders:
_______________________________________________
Proofreader.
_______________________________________________
Proofreader.
Sealed with the Great Seal and presented to the Governor, for his approval this
_______ day of _______________ at ________________________ o’clock, ________M.
______________________________________________
Speaker.
CHAPTER ______
1 AN ACT concerning
2 Pharmacy Benefits Administration – Maryland Medical Assistance Program and
3 Pharmacy Benefits Managers
4 Maryland Insurance Administration and Maryland Department of Health –
5 Workgroup to Study Pharmacy Benefits Managers
6 FOR the purpose of altering the reimbursement levels for drug products that the Maryland
7 Medical Assistance Program is required to establish and that pharmacy benefits
8 managers that contract with a pharmacy on behalf of a managed care organization
9 are required to reimburse the pharmacy; altering the definition of “purchaser” for
10 purposes of certain provisions of law regulating pharmacy benefits managers to
11 include certain insurers, nonprofit health service plans, and health maintenance
12 organizations requiring the Maryland Insurance Administration and the Maryland
EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from existing law.
Underlining indicates amendments to bill.
Strike out indicates matter stricken from the bill by amendment or deleted from the law by
amendment.
Italics indicate opposite chamber/conference co mm i tte e a m en dm en ts*. hb0813*
2 HOUSE BILL 813
1 Department of Health, in consultation with the Prescription Drug Affordability
2 Board, to convene a workgroup to study certain issues related to pharmacy benefits
3 managers and report to certain committees on or before a certain date; and generally
4 relating to pharmacy benefits administration a workgroup to study pharmacy
5 benefits managers.
6 BY repealing and reenacting, with amendments,
7 Article – Health – General
8 Section 15–118(b)
9 Annotated Code of Maryland
10 (2023 Replacement Volume and 2024 Supplement)
11 BY adding to
12 Article – Health – General
13 Section 15–118(f)
14 Annotated Code of Maryland
15 (2023 Replacement Volume and 2024 Supplement)
16 BY repealing and reenacting, with amendments,
17 Article – Insurance
18 Section 15–1601(s)
19 Annotated Code of Maryland
20 (2017 Replacement Volume and 2024 Supplement)
21 BY adding to
22 Article – Insurance
23 Section 15–1632
24 Annotated Code of Maryland
25 (2017 Replacement Volume and 2024 Supplement)
26 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
27 That the Laws of Maryland read as follows:
28 Article – Health – General
29 15–118.
30 (b) (1) [Except] SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION AND
31 EXCEPT as provided under paragraph [(2)] (3) of this subsection, the Program shall
32 establish [maximum] MINIMUM reimbursement levels for the drug products for which
33 there is a generic equivalent authorized under § 12–504 of the Health Occupations Article[,
34 based on the cost of the generic product].
35 (2) EXCEPT AS PROVIDED IN PARAGRAPH (4) OF THIS SUBSECTION,
36 MINIMUM REIMBURSEMENT LEVELS ESTABLISHED UNDER PARAGRAPH (1) OF THIS
37 SUBSECTION SHALL BE AT LEAST EQUAL TO THE NATIONAL AVERAGE DRUG
HOUSE BILL 813 3
1 ACQUISITION COST OF THE GENERIC PRODUCT PLUS THE FEE–FOR–SERVICE
2 PROFESSIONAL DISPENSING FEE DETERMINED BY THE DEPARTMENT IN
3 ACCORDANCE WITH THE MOST RECENT IN–STATE COST–OF–DISPENSING SURVEY.
4 [(2)] (3) [If] EXCEPT AS PROVIDED IN PARAGRAPH (4) OF THIS
5 SUBSECTION, IF a prescriber directs a specific brand name drug, the reimbursement level
6 shall be based on the [cost] NATIONAL AVERAGE DRUG ACQUISITION COST of the
7 brand name product PLUS THE FEE–FOR–SERVICE PROFESSIONAL DISPENSING FEE
8 DETERMINED BY THE DEPARTMENT IN ACCORDANCE WITH THE MOST RECENT
9 IN–STATE COST–OF–DISPENSING SURVEY.
10 (4) PARAGRAPHS (2) AND (3) OF THIS SUBSECTION DO NOT APPLY TO:
11 (I) A PHARMACY OWNED BY OR UNDER THE SAME CORPORATE
12 AFFILIATION AS A PHARMACY BENEFITS MANAGER; OR
13 (II) A MAIL ORDER PHARMACY.
14 (F) THE PROVISIONS OF § 15–1632 OF THE INSURANCE ARTICLE APPLY TO
15 A MANAGED CARE ORGANIZATION THAT USES A PHARMACY BENEFITS MANAGER TO
16 MANAGE PRESCRIPTION DRUG COVERAGE BENEFITS ON BEHALF OF THE MANAGED
17 CARE ORGANIZATION.
18 Article – Insurance
19 15–1601.
20 (s) (1) “Purchaser” means a person that offers a plan or program in the State,
21 including the State Employee and Retiree Health and Welfare Benefits Program, AN
22 INSURER, A NONPROFIT HEALTH SERVICE PLAN, OR A HEALTH MAINTENANCE
23 ORGANIZATION, that:
24 [(1)] (I) provides prescription drug coverage or benefits in the State; and
25 [(2)] (II) enters into an agreement with a pharmacy benefits manager for
26 the provision of pharmacy benefits management services.
27 (2) “PURCHASER” DOES NOT INCLUDE A NONPROFIT HEALTH
28 MAINTENANCE ORGANIZATION THAT:
29 (I) OPERATES AS A GROUP MODEL;
30 (II) PROVIDES SERVICES SOLELY TO A MEMBER OR PATIENT OF
31 THE NONPROFIT HEALTH MAINTENANCE ORGANIZATION; AND
4 HOUSE BILL 813
1 (III) FURNISHES SERVICES THROUGH THE INTERNAL PHARMACY
2 OPERATIONS OF THE NONPROFIT HEALTH MAINTENANCE ORGANIZATION.
3 15–1632.
4 A PHARMACY BENEFITS MANAGER THAT CONTRACTS WITH A PHARMACY ON
5 BEHALF OF A MANAGED CARE ORGANIZATION, AS DEFINED IN § 15–101 OF THE
6 HEALTH – GENERAL ARTICLE, SHALL REIMBURSE THE PHARMACY AN AMOUNT
7 THAT IS AT LEAST EQUAL TO THE NATIONAL AVERAGE DRUG ACQUISITION COST
8 PLUS THE FEE–FOR–SERVICE PROFESSIONAL DISPENSING FEE DETERMINED BY THE
9 MARYLAND DEPARTMENT OF HEALTH FOR THE MARYLAND MEDICAL ASSISTANCE
10 PROGRAM IN ACCORDANCE WITH THE MOST RECENT IN–STATE
11 COST–OF–DISPENSING SURVEY.
12 SECTION 2. AND BE IT FURTHER ENACTED, That this Act is an emergency
13 measure, is necessary for the immediate preservation of the public health or safety, has
14 been passed by a yea and nay vote supported by three–fifths of all the members elected to
15 each of the two Houses of the General Assembly, and shall take effect from the date it is
16 enacted.
17 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
18 That the Maryland Insurance Administration and the Maryland Department of Health, in
19 consultation with the Prescription Drug Affordability Board, shall:
20 (1) convene a workgroup of interested stakeholders, including community
21 pharmacies from both chain and independent settings, pharmacy services administrative
22 organizations, health insurance carriers, plan sponsor representatives, drug wholesalers
23 and distributors, non–pharmacy benefit manager–owned mail order pharmacies, brand
24 name and generic drug manufacturers, pharmacists, pharmacy benefits managers, and
25 managed care organizations, and third–party experts in the field of drug pricing in
26 Medicaid;
27 (2) review reimbursement for pharmacists, including:
28 (i) existing Maryland Medical Assistance Program requirements for
29 pharmacy benefits managers and managed care organizations related to dispensing fee
30 reimbursement, pharmacy benefits managers fees charged to pharmacies and the
31 Maryland Medical Assistance Program, transparency in pricing and reimbursement data,
32 specialty drug designations, and appeals processes;
33 (ii) how other states’ pharmacy benefits services operate in
34 Medicaid, including in Ohio, Kentucky, New York, California, and West Virginia;
HOUSE BILL 813 5
1 (iii) measures that offset the Department’s costs to fund the Medicaid
2 Managed Care Program and adopt NADAC plus the Fee–for–Service Professional
3 Dispensing, including:
4 1. savings associated with NADAC ingredient cost pricing
5 and managed care organizations; and
6 2. pharmacy benefits managers administrative fee
7 consolidation and rebate allocations; and
8 (iv) strategies for adopting pharmacy reimbursement parity and
9 drug pricing transparency;
10 (3) review coverage requirements for specialty drugs, including:
11 (i) which drugs are considered specialty for purposes of formularies
12 across carriers and pharmacy benefits managers; and
13 (ii) what these drugs have in common for purposes of developing a
14 new definition for “specialty drug”;
15 (4) review ERISA exemptions for pharmacy benefits management
16 regulation, including:
17 (i) the scope of Rutledge v. Pharmaceutical Care Management
18 Association and subsequent case law and federal guidance;
19 (ii) how other states have responded to the Rutledge decision; and
20 (iii) what, if any, other State laws should be amended;
21 (5) review the costs associated with pharmacies contracting with
22 commercial plans versus pharmacies contracting with the Maryland Medical Assistance
23 Program;
24 (6) review provisions of State law regarding pharmacy benefit managers,
25 specialty pharmacies, and anti–steering, including:
26 (i) § 15–1611.1 of the Insurance Article related to the use of specific
27 pharmacies or entities and the effect the section has on pharmacy costs in the fully insured
28 market; and
29 (ii) § 15–1612 of the Insurance Article related to reimbursement and
30 the effect the section has on pharmacy costs in the fully insured market;
31 (5) (7) on or before December 31, 2025, submit an interim report on their
32 findings and recommendations to the Senate Finance Committee and the House Health
6 HOUSE BILL 813
1 and Government Operations Committee, in accordance with § 2–1257 of the State
2 Government Article; and
3 (6) (8) on or before December 31, 2026, submit a final report on their findings
4 and recommendations to the Senate Finance Committee and the House Health and
5 Government Operations Committee, in accordance with § 2–1257 of the State Government
6 Article.
7 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect June
8 1, 2025.
Approved:
________________________________________________________________________________
Governor.
________________________________________________________________________________
Speaker of the House of Delegates.
________________________________________________________________________________
President of the Senate.
[DELETED: :CA    E ( M P R R R S w t G S a p t t G f h a t d o _ a _ o _ A P P M W F M p m a p o c p o l r p b m t i o]
[DELETED:  H  D o H i c w t P D A B m r t p b a a w t s p b B  A S  A  ( B  A S  A  ( B  A S  A  ( B  A S  A  (  S T A 1  ( ( Et ]S(  T  a p u p () o t s t P s]( e mmr l f t d p f w te, bt.    E()      S B A L E T T A V RA ]
[DELETED: H 3C– O O T G PTP T FEFRS   D F D B T E I NTTOFDS––    () If ]()[]E(X A P I P  O TN    s b b o t ct o t]NADAA V R C O b EFRS B T E I A W T M RNTTOFDS– .    P()()        )  R      ) AI    )T§12IH    N R   . A 1  (  “ i t S E a R H a W B P,AR A N H S PN O A H M      () p] (   () e] ( t    “PR D N I A N H     ) O    )IPN  ]
[DELETED:  H     )IF     O A M C ON A D I   O T§1 –GA  E RE S R T P A A  A V R C OADA EFRS DHMM E E A E S –S I A W T M R INTTOFD–   S m b e e  S T c   ( c p o h i c p s r d w a d n b m m o p b n a g d m p p b m a m c o a t e i t f o d p i M   ( r    ( e p r p b m f c t p a t M s    ( h o s p b s o i M]
[DELETED: H 5    ( m M C P a a N p t F P D     1 s a w N i c p a     2 p b m a f c    ( s f a p r p a d   ( r    ( w a    ( w n   ( r E e f p b m r    ( t s o R v P C M A    ( h    ( w   ( r t c a w p c w c P   ( r s    ( § p m    ( § t   ( o b D 3 2 s a i r o t f]
[DELETED:  H  a G O C i a w § 2 o t S G   ( a r t t S F C a t H H a G A  S 1          G               ]


================================================================================

Raw Text:
HOUSE BILL 813
J5 EMERGENCY BILL (5lr2785)
ENROLLED BILL
— Health and Government Operations/Finance —
Introduced by Delegates S. Johnson and A. Johnson, A. Johnson, Alston, Bagnall,
Bhandari, Cullison, Guzzone, Hill, Hutchinson, Kaiser, Kerr, Kipke, Lopez,
Martinez, M. Morgan, Pena–Melnyk, Reilly, Rosenberg, Ross, Szeliga,
Taveras, White Holland, Woods, and Woorman
Read and Examined by Proofreaders:
_______________________________________________
Proofreader.
_______________________________________________
Proofreader.
Sealed with the Great Seal and presented to the Governor, for his approval this
_______ day of _______________ at ________________________ o’clock, ________M.
______________________________________________
Speaker.
CHAPTER ______
1 AN ACT concerning
2 Pharmacy Benefits Administration – Maryland Medical Assistance Program and
3 Pharmacy Benefits Managers
4 Maryland Insurance Administration and Maryland Department of Health –
5 Workgroup to Study Pharmacy Benefits Managers
6 FOR the purpose of altering the reimbursement levels for drug products that the Maryland
7 Medical Assistance Program is required to establish and that pharmacy benefits
8 managers that contract with a pharmacy on behalf of a managed care organization
9 are required to reimburse the pharmacy; altering the definition of “purchaser” for
10 purposes of certain provisions of law regulating pharmacy benefits managers to
11 include certain insurers, nonprofit health service plans, and health maintenance
12 organizations requiring the Maryland Insurance Administration and the Maryland
EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from existing law.
Underlining indicates amendments to bill.
Strike out indicates matter stricken from the bill by amendment or deleted from the law by
amendment.
Italics indicate opposite chamber/conference co mm i tte e a m en dm en ts*. hb0813*

2 HOUSE BILL 813
1 Department of Health, in consultation with the Prescription Drug Affordability
2 Board, to convene a workgroup to study certain issues related to pharmacy benefits
3 managers and report to certain committees on or before a certain date; and generally
4 relating to pharmacy benefits administration a workgroup to study pharmacy
5 benefits managers.
6 BY repealing and reenacting, with amendments,
7 Article – Health – General
8 Section 15–118(b)
9 Annotated Code of Maryland
10 (2023 Replacement Volume and 2024 Supplement)
11 BY adding to
12 Article – Health – General
13 Section 15–118(f)
14 Annotated Code of Maryland
15 (2023 Replacement Volume and 2024 Supplement)
16 BY repealing and reenacting, with amendments,
17 Article – Insurance
18 Section 15–1601(s)
19 Annotated Code of Maryland
20 (2017 Replacement Volume and 2024 Supplement)
21 BY adding to
22 Article – Insurance
23 Section 15–1632
24 Annotated Code of Maryland
25 (2017 Replacement Volume and 2024 Supplement)
26 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
27 That the Laws of Maryland read as follows:
28 Article – Health – General
29 15–118.
30 (b) (1) [Except] SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION AND
31 EXCEPT as provided under paragraph [(2)] (3) of this subsection, the Program shall
32 establish [maximum] MINIMUM reimbursement levels for the drug products for which
33 there is a generic equivalent authorized under § 12–504 of the Health Occupations Article[,
34 based on the cost of the generic product].
35 (2) EXCEPT AS PROVIDED IN PARAGRAPH (4) OF THIS SUBSECTION,
36 MINIMUM REIMBURSEMENT LEVELS ESTABLISHED UNDER PARAGRAPH (1) OF THIS
37 SUBSECTION SHALL BE AT LEAST EQUAL TO THE NATIONAL AVERAGE DRUG

HOUSE BILL 813 3
1 ACQUISITION COST OF THE GENERIC PRODUCT PLUS THE FEE–FOR–SERVICE
2 PROFESSIONAL DISPENSING FEE DETERMINED BY THE DEPARTMENT IN
3 ACCORDANCE WITH THE MOST RECENT IN–STATE COST–OF–DISPENSING SURVEY.
4 [(2)] (3) [If] EXCEPT AS PROVIDED IN PARAGRAPH (4) OF THIS
5 SUBSECTION, IF a prescriber directs a specific brand name drug, the reimbursement level
6 shall be based on the [cost] NATIONAL AVERAGE DRUG ACQUISITION COST of the
7 brand name product PLUS THE FEE–FOR–SERVICE PROFESSIONAL DISPENSING FEE
8 DETERMINED BY THE DEPARTMENT IN ACCORDANCE WITH THE MOST RECENT
9 IN–STATE COST–OF–DISPENSING SURVEY.
10 (4) PARAGRAPHS (2) AND (3) OF THIS SUBSECTION DO NOT APPLY TO:
11 (I) A PHARMACY OWNED BY OR UNDER THE SAME CORPORATE
12 AFFILIATION AS A PHARMACY BENEFITS MANAGER; OR
13 (II) A MAIL ORDER PHARMACY.
14 (F) THE PROVISIONS OF § 15–1632 OF THE INSURANCE ARTICLE APPLY TO
15 A MANAGED CARE ORGANIZATION THAT USES A PHARMACY BENEFITS MANAGER TO
16 MANAGE PRESCRIPTION DRUG COVERAGE BENEFITS ON BEHALF OF THE MANAGED
17 CARE ORGANIZATION.
18 Article – Insurance
19 15–1601.
20 (s) (1) “Purchaser” means a person that offers a plan or program in the State,
21 including the State Employee and Retiree Health and Welfare Benefits Program, AN
22 INSURER, A NONPROFIT HEALTH SERVICE PLAN, OR A HEALTH MAINTENANCE
23 ORGANIZATION, that:
24 [(1)] (I) provides prescription drug coverage or benefits in the State; and
25 [(2)] (II) enters into an agreement with a pharmacy benefits manager for
26 the provision of pharmacy benefits management services.
27 (2) “PURCHASER” DOES NOT INCLUDE A NONPROFIT HEALTH
28 MAINTENANCE ORGANIZATION THAT:
29 (I) OPERATES AS A GROUP MODEL;
30 (II) PROVIDES SERVICES SOLELY TO A MEMBER OR PATIENT OF
31 THE NONPROFIT HEALTH MAINTENANCE ORGANIZATION; AND

4 HOUSE BILL 813
1 (III) FURNISHES SERVICES THROUGH THE INTERNAL PHARMACY
2 OPERATIONS OF THE NONPROFIT HEALTH MAINTENANCE ORGANIZATION.
3 15–1632.
4 A PHARMACY BENEFITS MANAGER THAT CONTRACTS WITH A PHARMACY ON
5 BEHALF OF A MANAGED CARE ORGANIZATION, AS DEFINED IN § 15–101 OF THE
6 HEALTH – GENERAL ARTICLE, SHALL REIMBURSE THE PHARMACY AN AMOUNT
7 THAT IS AT LEAST EQUAL TO THE NATIONAL AVERAGE DRUG ACQUISITION COST
8 PLUS THE FEE–FOR–SERVICE PROFESSIONAL DISPENSING FEE DETERMINED BY THE
9 MARYLAND DEPARTMENT OF HEALTH FOR THE MARYLAND MEDICAL ASSISTANCE
10 PROGRAM IN ACCORDANCE WITH THE MOST RECENT IN–STATE
11 COST–OF–DISPENSING SURVEY.
12 SECTION 2. AND BE IT FURTHER ENACTED, That this Act is an emergency
13 measure, is necessary for the immediate preservation of the public health or safety, has
14 been passed by a yea and nay vote supported by three–fifths of all the members elected to
15 each of the two Houses of the General Assembly, and shall take effect from the date it is
16 enacted.
17 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
18 That the Maryland Insurance Administration and the Maryland Department of Health, in
19 consultation with the Prescription Drug Affordability Board, shall:
20 (1) convene a workgroup of interested stakeholders, including community
21 pharmacies from both chain and independent settings, pharmacy services administrative
22 organizations, health insurance carriers, plan sponsor representatives, drug wholesalers
23 and distributors, non–pharmacy benefit manager–owned mail order pharmacies, brand
24 name and generic drug manufacturers, pharmacists, pharmacy benefits managers, and
25 managed care organizations, and third–party experts in the field of drug pricing in
26 Medicaid;
27 (2) review reimbursement for pharmacists, including:
28 (i) existing Maryland Medical Assistance Program requirements for
29 pharmacy benefits managers and managed care organizations related to dispensing fee
30 reimbursement, pharmacy benefits managers fees charged to pharmacies and the
31 Maryland Medical Assistance Program, transparency in pricing and reimbursement data,
32 specialty drug designations, and appeals processes;
33 (ii) how other states’ pharmacy benefits services operate in
34 Medicaid, including in Ohio, Kentucky, New York, California, and West Virginia;

HOUSE BILL 813 5
1 (iii) measures that offset the Department’s costs to fund the Medicaid
2 Managed Care Program and adopt NADAC plus the Fee–for–Service Professional
3 Dispensing, including:
4 1. savings associated with NADAC ingredient cost pricing
5 and managed care organizations; and
6 2. pharmacy benefits managers administrative fee
7 consolidation and rebate allocations; and
8 (iv) strategies for adopting pharmacy reimbursement parity and
9 drug pricing transparency;
10 (3) review coverage requirements for specialty drugs, including:
11 (i) which drugs are considered specialty for purposes of formularies
12 across carriers and pharmacy benefits managers; and
13 (ii) what these drugs have in common for purposes of developing a
14 new definition for “specialty drug”;
15 (4) review ERISA exemptions for pharmacy benefits management
16 regulation, including:
17 (i) the scope of Rutledge v. Pharmaceutical Care Management
18 Association and subsequent case law and federal guidance;
19 (ii) how other states have responded to the Rutledge decision; and
20 (iii) what, if any, other State laws should be amended;
21 (5) review the costs associated with pharmacies contracting with
22 commercial plans versus pharmacies contracting with the Maryland Medical Assistance
23 Program;
24 (6) review provisions of State law regarding pharmacy benefit managers,
25 specialty pharmacies, and anti–steering, including:
26 (i) § 15–1611.1 of the Insurance Article related to the use of specific
27 pharmacies or entities and the effect the section has on pharmacy costs in the fully insured
28 market; and
29 (ii) § 15–1612 of the Insurance Article related to reimbursement and
30 the effect the section has on pharmacy costs in the fully insured market;
31 (5) (7) on or before December 31, 2025, submit an interim report on their
32 findings and recommendations to the Senate Finance Committee and the House Health

6 HOUSE BILL 813
1 and Government Operations Committee, in accordance with § 2–1257 of the State
2 Government Article; and
3 (6) (8) on or before December 31, 2026, submit a final report on their findings
4 and recommendations to the Senate Finance Committee and the House Health and
5 Government Operations Committee, in accordance with § 2–1257 of the State Government
6 Article.
7 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect June
8 1, 2025.
Approved:
________________________________________________________________________________
Governor.
________________________________________________________________________________
Speaker of the House of Delegates.
________________________________________________________________________________
President of the Senate.

[DELETED: :CA    E ( M P R R R S w t G S a p t t G f h a t d o _ a _ o _ A P P M W F M p m a p o c p o l r p b m t i o]
[DELETED:  H  D o H i c w t P D A B m r t p b a a w t s p b B  A S  A  ( B  A S  A  ( B  A S  A  ( B  A S  A  (  S T A 1  ( ( Et ]S(  T  a p u p () o t s t P s]( e mmr l f t d p f w te, bt.    E()      S B A L E T T A V RA ]
[DELETED: H 3C– O O T G PTP T FEFRS   D F D B T E I NTTOFDS––    () If ]()[]E(X A P I P  O TN    s b b o t ct o t]NADAA V R C O b EFRS B T E I A W T M RNTTOFDS– .    P()()        )  R      ) AI    )T§12IH    N R   . A 1  (  “ i t S E a R H a W B P,AR A N H S PN O A H M      () p] (   () e] ( t    “PR D N I A N H     ) O    )IPN  ]
[DELETED:  H     )IF     O A M C ON A D I   O T§1 –GA  E RE S R T P A A  A V R C OADA EFRS DHMM E E A E S –S I A W T M R INTTOFD–   S m b e e  S T c   ( c p o h i c p s r d w a d n b m m o p b n a g d m p p b m a m c o a t e i t f o d p i M   ( r    ( e p r p b m f c t p a t M s    ( h o s p b s o i M]
[DELETED: H 5    ( m M C P a a N p t F P D     1 s a w N i c p a     2 p b m a f c    ( s f a p r p a d   ( r    ( w a    ( w n   ( r E e f p b m r    ( t s o R v P C M A    ( h    ( w   ( r t c a w p c w c P   ( r s    ( § p m    ( § t   ( o b D 3 2 s a i r o t f]
[DELETED:  H  a G O C i a w § 2 o t S G   ( a r t t S F C a t H H a G A  S 1          G               ]